
Quiz|Articles|April 24, 2026
OncLive Weekly News Quiz (4/24/2026): Test Your Knowledge on Key Bladder and Kidney Cancer Updates
Author(s)OncLive Staff
Fact checked by: Chris Ryan
Key Takeaways
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
The FDA granted priority review to perioperative enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for patients with cisplatin-eligible muscle-invasive bladder cancer based on which key finding from the phase 3 KEYNOTE-B15 trial (NCT04700124)?
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
Vopimetostat Plus Daraxonrasib Yields 92% ORR in MTAP-Deleted, RAS-Mutant Pancreatic Cancer
2
KEYNOTE-D46 Trial Is Discontinued With Sacituzumab Govitecan Plus Pembrolizumab in PD-L1–High NSCLC
3
GU Cancer Experts Highlight the Most Impactful and Discussion-Worthy Data Presented at ASCO 2026
4
Subcutaneous Isatuximab Administered Via OBI Approved in EU for Multiple Myeloma
5






































































